公开(公告)号：EP2344484B1

公开(公告)日：2016-06-08

申请号：EP09820119.7

申请日：2009-10-19

申请人： Akaal Pharma Pty Ltd

发明人： GROBELNY, Damian W ,  GILL, Gurmit S

IPC分类号： C07D413/10 ,  A61P31/04 ,  C07D209/08 ,  A61K31/16 ,  A61P31/12 ,  C07D215/18 ,  A61K31/18 ,  A61K31/343 ,  A61K31/382 ,  A61K31/397 ,  A61K31/403 ,  A61K31/4164 ,  A61P9/00 ,  A61P11/00 ,  A61P29/00 ,  A61P31/00 ,  C07C225/16 ,  C07D295/104 ,  C07D333/20 ,  A61P33/00 ,  A61P35/00

CPC分类号： A61K31/343 ,  A61K31/16 ,  A61K31/18 ,  A61K31/382 ,  A61K31/397 ,  A61K31/403 ,  A61K31/41 ,  A61K31/4164 ,  A61K31/4245 ,  C07C33/26 ,  C07C215/10 ,  C07C215/14 ,  C07C215/16 ,  C07C229/16 ,  C07C275/24 ,  C07C275/28 ,  C07C281/06 ,  C07C2602/42 ,  C07C2603/74 ,  C07D205/04 ,  C07D209/04 ,  C07D209/08 ,  C07D215/18 ,  C07D233/32 ,  C07D241/12 ,  C07D257/04 ,  C07D295/104 ,  C07D307/79 ,  C07D307/81 ,  C07D311/22 ,  C07D333/04 ,  C07D333/20 ,  C07D413/04 ,  C07D413/10 ,  C07D413/14 ,  C07F9/094 ,  C07F9/65586 ,  Y02A50/402 ,  Y02A50/47

摘要： The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.

公开(公告)号：EP3334428A1

公开(公告)日：2018-06-20

申请号：EP16834321.8

申请日：2016-08-11

申请人： Akaal Pharma Pty Ltd

发明人： GILL, Gurmit S. ,  GROBELNY, Damian W

IPC分类号： A61K31/4245 ,  A61K31/56 ,  A61K31/573 ,  A61K31/192 ,  A61P17/00 ,  A61K31/343 ,  A61K31/485

CPC分类号： A61K31/4245 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0024 ,  A61K9/0031 ,  A61K9/0043 ,  A61K9/0046 ,  A61K9/0048 ,  A61K9/0053 ,  A61K9/0095 ,  A61K9/06 ,  A61K9/08 ,  A61K9/10 ,  A61K9/107 ,  A61K9/12 ,  A61K9/2004 ,  A61K9/48 ,  A61K9/7038 ,  A61K31/165 ,  A61K31/167 ,  A61K31/192 ,  A61K31/196 ,  A61K31/197 ,  A61K31/355 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/455 ,  A61K31/485 ,  A61K31/573 ,  A61K45/06 ,  A61K47/10 ,  A61K47/14 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38 ,  A61K47/44 ,  A61K2300/00

摘要： Compositions comprising S1P receptor modulators and at least one compound selected from one or more of the group consisting of steroids, opioids and non-steroidal anti-inflammatory drugs are provided. The compositions find use in the treatment of disease, particularly inflammation and immune mediated disorders.

公开(公告)号：EP2344484A1

公开(公告)日：2011-07-20

申请号：EP09820119.7

申请日：2009-10-19

申请人： Akaal Pharma Pty Ltd

发明人： GROBELNY, Damian W ,  GILL, Gurmit S

IPC分类号： C07D413/10 ,  A61P31/04 ,  C07D209/08 ,  A61K31/16 ,  A61P31/12 ,  C07D215/18 ,  A61K31/18 ,  A61K31/343 ,  A61K31/382 ,  A61K31/397 ,  A61K31/403 ,  A61K31/4164 ,  A61P9/00 ,  A61P11/00 ,  A61P29/00 ,  A61P31/00 ,  C07C225/16 ,  C07D295/104 ,  C07D333/20 ,  A61P33/00 ,  A61P35/00

CPC分类号： A61K31/343 ,  A61K31/16 ,  A61K31/18 ,  A61K31/382 ,  A61K31/397 ,  A61K31/403 ,  A61K31/41 ,  A61K31/4164 ,  A61K31/4245 ,  C07C33/26 ,  C07C215/10 ,  C07C215/14 ,  C07C215/16 ,  C07C229/16 ,  C07C275/24 ,  C07C275/28 ,  C07C281/06 ,  C07C2602/42 ,  C07C2603/74 ,  C07D205/04 ,  C07D209/04 ,  C07D209/08 ,  C07D215/18 ,  C07D233/32 ,  C07D241/12 ,  C07D257/04 ,  C07D295/104 ,  C07D307/79 ,  C07D307/81 ,  C07D311/22 ,  C07D333/04 ,  C07D333/20 ,  C07D413/04 ,  C07D413/10 ,  C07D413/14 ,  C07F9/094 ,  C07F9/65586 ,  Y02A50/402 ,  Y02A50/47

摘要： The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.